PE20011008A1 - Derivados de pirimidina como inhibidores de ciclooxigenasa 2 - Google Patents
Derivados de pirimidina como inhibidores de ciclooxigenasa 2Info
- Publication number
- PE20011008A1 PE20011008A1 PE2000001249A PE0012492000A PE20011008A1 PE 20011008 A1 PE20011008 A1 PE 20011008A1 PE 2000001249 A PE2000001249 A PE 2000001249A PE 0012492000 A PE0012492000 A PE 0012492000A PE 20011008 A1 PE20011008 A1 PE 20011008A1
- Authority
- PE
- Peru
- Prior art keywords
- trifluoromethyl
- pyrimidin
- amine
- phenyl
- cyclooxygenase
- Prior art date
Links
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- BQDJLAWUTBCDHK-UHFFFAOYSA-N 2-(trifluoromethyl)pyrimidine Chemical class FC(F)(F)C1=NC=CC=N1 BQDJLAWUTBCDHK-UHFFFAOYSA-N 0.000 abstract 1
- -1 CYCLOBUTYLMETHYL Chemical class 0.000 abstract 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
Abstract
SE REFIERE A DERIVADOS DE TRIFLUOROMETIL PIRIMIDINA DONDE R1 Y R2 SON H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C3-C6, CICLOALQUILO C3-C10-ALQUILO C0-C6; R3 ES ALQUILO C1-C6, NH2. SON COMPUESTOS PREFERIDOS N-CICLOPENTIL-4-[4-(METILSULFONIL)FENIL]-6-(TRIFLUOROMETIL)PIRIMIDIN-2-AMINA; N-CICLOHEXIL-4-[4-(METILSULFONIL)FENIL]-6-(TRIFLUOROMETIL)PIRIMIDIN-2-AMINA; N-ISOBUTIL-4-[4-(METILSULFONIL)FENIL]-6-(TRIFLUOROMETIL)PIRIMIDIN-2-AMINA; N-(CICLOBUTILMETIL)-4-[4-(METILSULFONIL)FENIL]-6-(TRIFLUOROMETIL)PIRIMIDIN-2-AMINA. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL COMPUESTO I ES UN INHIBIDOR DE CICLOOXIGENASA 2 Y PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA ALTERACION INFLAMATORIA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9927844.2A GB9927844D0 (en) | 1999-11-26 | 1999-11-26 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011008A1 true PE20011008A1 (es) | 2001-10-15 |
Family
ID=10865107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001249A PE20011008A1 (es) | 1999-11-26 | 2000-11-23 | Derivados de pirimidina como inhibidores de ciclooxigenasa 2 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6780869B1 (es) |
| EP (1) | EP1235812B1 (es) |
| JP (1) | JP2003514898A (es) |
| KR (1) | KR20020063899A (es) |
| CN (1) | CN1399633A (es) |
| AT (1) | ATE316962T1 (es) |
| AU (1) | AU2508401A (es) |
| BR (1) | BR0015821A (es) |
| CA (1) | CA2395049A1 (es) |
| CO (1) | CO5271666A1 (es) |
| CZ (1) | CZ20021802A3 (es) |
| DE (1) | DE60025848T2 (es) |
| ES (1) | ES2256086T3 (es) |
| GB (1) | GB9927844D0 (es) |
| HU (1) | HUP0203385A3 (es) |
| IL (1) | IL149586A0 (es) |
| MX (1) | MXPA02005231A (es) |
| NO (1) | NO20022470L (es) |
| PE (1) | PE20011008A1 (es) |
| PL (1) | PL356237A1 (es) |
| WO (1) | WO2001038311A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9927844D0 (en) | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| GB0112810D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0112802D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0112803D0 (en) * | 2001-05-25 | 2001-07-18 | Glaxo Group Ltd | Pyrimidine derivatives |
| GB0119477D0 (en) * | 2001-08-09 | 2001-10-03 | Glaxo Group Ltd | Pyrimidine derivatives |
| EP1437338B1 (en) * | 2001-10-10 | 2009-09-16 | Hitachi High-Technologies Corporation | Luminous compounds and labeling reagents using the same |
| AU2003246864A1 (en) * | 2002-02-22 | 2003-09-09 | Warner-Lambert Company Llc | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 |
| DE60305053T2 (de) * | 2002-08-19 | 2006-08-31 | Glaxo Group Ltd., Greenford | Pyrimidinderivate als selektive cox-2-inhibitoren |
| UY27939A1 (es) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| GB0221443D0 (en) * | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| GB0227443D0 (en) * | 2002-11-25 | 2002-12-31 | Glaxo Group Ltd | Pyrimidine derivatives |
| WO2005000227A2 (en) * | 2003-06-06 | 2005-01-06 | Intermune, Inc. | Methods of treating tnf-mediated disorders |
| GB0319037D0 (en) * | 2003-08-13 | 2003-09-17 | Glaxo Group Ltd | 7-Azaindole Derivatives |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| CN102438993A (zh) * | 2009-05-19 | 2012-05-02 | 陶氏益农公司 | 用于控制真菌的化合物和方法 |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| ES2529233T3 (es) | 2010-07-09 | 2015-02-18 | Convergence Pharmaceuticals Limited | Compuestos tetrazol como bloqueadores de canales de calcio |
| AU2016222804C1 (en) | 2015-02-25 | 2021-10-14 | The Regents Of The University Of California | 5HT agonists for treating disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020343A (en) | 1995-10-13 | 2000-02-01 | Merck Frosst Canada, Inc. | (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors |
| CN1152863C (zh) | 1996-07-18 | 2004-06-09 | 麦克弗罗斯特(加拿大)公司 | 作为环氧合酶-2选择性抑制剂的取代的吡啶类化合物及其组合物 |
| TW520362B (en) | 1996-12-05 | 2003-02-11 | Amgen Inc | Substituted pyrimidine compounds and pharmaceutical composition comprising same |
| GB9927844D0 (en) | 1999-11-26 | 2000-01-26 | Glaxo Group Ltd | Chemical compounds |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
-
1999
- 1999-11-26 GB GBGB9927844.2A patent/GB9927844D0/en not_active Ceased
-
2000
- 2000-11-23 PE PE2000001249A patent/PE20011008A1/es not_active Application Discontinuation
- 2000-11-23 DE DE60025848T patent/DE60025848T2/de not_active Expired - Fee Related
- 2000-11-23 KR KR1020027006732A patent/KR20020063899A/ko not_active Withdrawn
- 2000-11-23 CN CN00816293A patent/CN1399633A/zh active Pending
- 2000-11-23 US US10/130,516 patent/US6780869B1/en not_active Expired - Fee Related
- 2000-11-23 ES ES00988751T patent/ES2256086T3/es not_active Expired - Lifetime
- 2000-11-23 AU AU25084/01A patent/AU2508401A/en not_active Abandoned
- 2000-11-23 EP EP00988751A patent/EP1235812B1/en not_active Expired - Lifetime
- 2000-11-23 JP JP2001540074A patent/JP2003514898A/ja active Pending
- 2000-11-23 PL PL00356237A patent/PL356237A1/xx not_active Application Discontinuation
- 2000-11-23 AT AT00988751T patent/ATE316962T1/de not_active IP Right Cessation
- 2000-11-23 IL IL14958600A patent/IL149586A0/xx unknown
- 2000-11-23 BR BR0015821-6A patent/BR0015821A/pt not_active Application Discontinuation
- 2000-11-23 CZ CZ20021802A patent/CZ20021802A3/cs unknown
- 2000-11-23 WO PCT/EP2000/011673 patent/WO2001038311A2/en not_active Ceased
- 2000-11-23 CA CA002395049A patent/CA2395049A1/en not_active Abandoned
- 2000-11-23 MX MXPA02005231A patent/MXPA02005231A/es unknown
- 2000-11-23 HU HU0203385A patent/HUP0203385A3/hu unknown
- 2000-11-24 CO CO00090138A patent/CO5271666A1/es not_active Application Discontinuation
-
2002
- 2002-05-24 NO NO20022470A patent/NO20022470L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL356237A1 (en) | 2004-06-28 |
| WO2001038311A3 (en) | 2001-11-01 |
| IL149586A0 (en) | 2002-11-10 |
| NO20022470D0 (no) | 2002-05-24 |
| WO2001038311A2 (en) | 2001-05-31 |
| GB9927844D0 (en) | 2000-01-26 |
| DE60025848D1 (en) | 2006-04-13 |
| CO5271666A1 (es) | 2003-04-30 |
| EP1235812B1 (en) | 2006-02-01 |
| BR0015821A (pt) | 2002-07-30 |
| HUP0203385A2 (en) | 2003-05-28 |
| CA2395049A1 (en) | 2001-05-31 |
| HUP0203385A3 (en) | 2003-07-28 |
| EP1235812A2 (en) | 2002-09-04 |
| JP2003514898A (ja) | 2003-04-22 |
| KR20020063899A (ko) | 2002-08-05 |
| CZ20021802A3 (cs) | 2002-10-16 |
| ATE316962T1 (de) | 2006-02-15 |
| MXPA02005231A (es) | 2002-11-07 |
| AU2508401A (en) | 2001-06-04 |
| NO20022470L (no) | 2002-07-18 |
| ES2256086T3 (es) | 2006-07-16 |
| DE60025848T2 (de) | 2006-08-03 |
| CN1399633A (zh) | 2003-02-26 |
| US6780869B1 (en) | 2004-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011008A1 (es) | Derivados de pirimidina como inhibidores de ciclooxigenasa 2 | |
| PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
| PE20011259A1 (es) | Derivado de piridina y pirimidina | |
| UY27055A1 (es) | Activadores heteroaromaticos fusionados de la glucoquinasa | |
| PE20030200A1 (es) | Bencimidazol como inhibidores de las map quinasas | |
| WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
| DE60034961D1 (de) | Aminobenzophenone als inhibitoren von il-1beta und tnf-alpha | |
| EA199900591A1 (ru) | АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха | |
| ATE449099T1 (de) | Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren | |
| PE20010635A1 (es) | Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas | |
| PE20060215A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| AR059249A1 (es) | Compuesto amina trisustituido | |
| PE20010070A1 (es) | COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2 | |
| PE20040592A1 (es) | Antagonistas de cgrp elegidos, procedimiento para su preparacion | |
| PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
| PL376728A1 (pl) | Indole użyteczne do leczenia chorób związanych z receptorem androgenowym | |
| EP1176958A4 (en) | NEW CATHECHOLE AS AN ANTIMICROBIAL AGENT | |
| UA81561C2 (en) | Use of n-arylhydrazine derivative and method for controlling non-crop pests | |
| PE20010989A1 (es) | 8-arilquinolinas sustituidas inhibidoras de 4-fosfodiesterasa | |
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| WO2006123165A3 (en) | Pyrimidine derivatives as hsp90 inhibitors | |
| DK1202954T3 (da) | Nye aminobenzophenoner | |
| EP1357124A4 (en) | HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS | |
| EA199901096A1 (ru) | Цианогуанидины в качестве ингибиторов пролиферации клеток | |
| CO5261560A1 (es) | Nuevos derivados de tiazolidindiona como agentes antidiabeticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |